Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival-a systematic review and meta-analysis.
Antibiotic therapy
Intensive care
Procalcitonin
Sepsis
Journal
Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902
Informations de publication
Date de publication:
13 10 2023
13 10 2023
Historique:
received:
20
07
2023
accepted:
04
10
2023
medline:
23
10
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Appropriate antibiotic (AB) therapy remains a challenge in the intensive care unit (ICU). Procalcitonin (PCT)-guided AB stewardship could help optimize AB treatment and decrease AB-related adverse effects, but firm evidence is still lacking. Our aim was to compare the effects of PCT-guided AB therapy with standard of care (SOC) in critically ill patients. We searched databases CENTRAL, Embase and Medline. We included randomized controlled trials (RCTs) comparing PCT-guided AB therapy (PCT group) with SOC reporting on length of AB therapy, mortality, recurrent and secondary infection, ICU length of stay (LOS), hospital LOS or healthcare costs. Due to recent changes in sepsis definitions, subgroup analyses were performed in studies applying the Sepsis-3 definition. In the statistical analysis, a random-effects model was used to pool effect sizes. We included 26 RCTs (n = 9048 patients) in the quantitative analysis. In comparison with SOC, length of AB therapy was significantly shorter in the PCT group (MD - 1.79 days, 95% CI: -2.65, - 0.92) and was associated with a significantly lower 28-day mortality (OR 0.84, 95% CI: 0.74, 0.95). In Sepsis-3 patients, mortality benefit was more pronounced (OR 0.46 95% CI: 0.27, 0.79). Odds of recurrent infection were significantly higher in the PCT group (OR 1.36, 95% CI: 1.10, 1.68), but there was no significant difference in the odds of secondary infection (OR 0.81, 95% CI: 0.54, 1.21), ICU and hospital length of stay (MD - 0.67 days 95% CI: - 1.76, 0.41 and MD - 1.23 days, 95% CI: - 3.13, 0.67, respectively). PCT-guided AB therapy may be associated with reduced AB use, lower 28-day mortality but higher infection recurrence, with similar ICU and hospital length of stay. Our results render the need for better designed studies investigating the role of PCT-guided AB stewardship in critically ill patients.
Sections du résumé
BACKGROUND
Appropriate antibiotic (AB) therapy remains a challenge in the intensive care unit (ICU). Procalcitonin (PCT)-guided AB stewardship could help optimize AB treatment and decrease AB-related adverse effects, but firm evidence is still lacking. Our aim was to compare the effects of PCT-guided AB therapy with standard of care (SOC) in critically ill patients.
METHODS
We searched databases CENTRAL, Embase and Medline. We included randomized controlled trials (RCTs) comparing PCT-guided AB therapy (PCT group) with SOC reporting on length of AB therapy, mortality, recurrent and secondary infection, ICU length of stay (LOS), hospital LOS or healthcare costs. Due to recent changes in sepsis definitions, subgroup analyses were performed in studies applying the Sepsis-3 definition. In the statistical analysis, a random-effects model was used to pool effect sizes.
RESULTS
We included 26 RCTs (n = 9048 patients) in the quantitative analysis. In comparison with SOC, length of AB therapy was significantly shorter in the PCT group (MD - 1.79 days, 95% CI: -2.65, - 0.92) and was associated with a significantly lower 28-day mortality (OR 0.84, 95% CI: 0.74, 0.95). In Sepsis-3 patients, mortality benefit was more pronounced (OR 0.46 95% CI: 0.27, 0.79). Odds of recurrent infection were significantly higher in the PCT group (OR 1.36, 95% CI: 1.10, 1.68), but there was no significant difference in the odds of secondary infection (OR 0.81, 95% CI: 0.54, 1.21), ICU and hospital length of stay (MD - 0.67 days 95% CI: - 1.76, 0.41 and MD - 1.23 days, 95% CI: - 3.13, 0.67, respectively).
CONCLUSIONS
PCT-guided AB therapy may be associated with reduced AB use, lower 28-day mortality but higher infection recurrence, with similar ICU and hospital length of stay. Our results render the need for better designed studies investigating the role of PCT-guided AB stewardship in critically ill patients.
Identifiants
pubmed: 37833778
doi: 10.1186/s13054-023-04677-2
pii: 10.1186/s13054-023-04677-2
pmc: PMC10576288
doi:
Substances chimiques
Procalcitonin
0
Biomarkers
0
Anti-Bacterial Agents
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
394Subventions
Organisme : Hungarian National Research, Development and Innovation Office
ID : K 138816
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Med Clin North Am. 2013 Jul;97(4):667-79, xi
pubmed: 23809719
Crit Care Med. 2003 Apr;31(4):1250-6
pubmed: 12682500
Ir J Med Sci. 2021 Nov;190(4):1487-1495
pubmed: 33447966
J Public Health (Oxf). 2022 Dec 1;44(4):e588-e592
pubmed: 35352103
Crit Care Med. 2011 Sep;39(9):2048-58
pubmed: 21572328
BMC Infect Dis. 2013 Dec 17;13:596
pubmed: 24341820
J Natl Cancer Inst. 1959 Apr;22(4):719-48
pubmed: 13655060
J Infect Dis. 2015 Dec 1;212(11):1692-700
pubmed: 25910632
Respir Investig. 2014 Mar;52(2):107-13
pubmed: 24636266
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Crit Care. 2018 Nov 13;22(1):293
pubmed: 30424796
Indian J Crit Care Med. 2021 May;25(5):507-511
pubmed: 34177168
Zhonghua Yi Xue Za Zhi. 2017 Feb 7;97(5):343-346
pubmed: 28219190
Am J Respir Crit Care Med. 2006 Jul 1;174(1):84-93
pubmed: 16603606
Crit Care Med. 2000 Jun;28(6):1828-32
pubmed: 10890628
Clin Microbiol Infect. 2018 Dec;24(12):1282-1289
pubmed: 29870855
Expert Rev Anti Infect Ther. 2022 Jan;20(1):103-112
pubmed: 34027785
JAMA. 2019 Oct 15;322(15):1476-1485
pubmed: 31577035
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Intensive Care Med. 2018 Apr;44(4):428-437
pubmed: 29663044
Lancet. 2004 Feb 21;363(9409):600-7
pubmed: 14987884
Lancet Infect Dis. 2016 Jul;16(7):819-827
pubmed: 26947523
Clin Microbiol Infect. 2009 May;15(5):481-7
pubmed: 19416298
J Crit Care. 2016 Aug;34:50-5
pubmed: 27288610
Diagn Microbiol Infect Dis. 2013 Jul;76(3):266-71
pubmed: 23711530
Eur Respir J. 2009 Dec;34(6):1364-75
pubmed: 19797133
Crit Care Med. 2012 Aug;40(8):2304-9
pubmed: 22809906
Int J Chron Obstruct Pulmon Dis. 2016 Jun 22;11:1381-9
pubmed: 27382274
Crit Care. 2015 Sep 07;19:319
pubmed: 26346055
Eur Respir J. 2010 Sep;36(3):601-7
pubmed: 20185423
Crit Care Med. 2017 Feb;45(2):337-347
pubmed: 28098630
Iran J Public Health. 2017 Nov;46(11):1535-1539
pubmed: 29167772
Respirology. 2011 Jul;16(5):819-24
pubmed: 21507143
Langenbecks Arch Surg. 2009 Mar;394(2):221-6
pubmed: 19034493
Crit Care Med. 2013 Oct;41(10):2336-43
pubmed: 23921272
Srp Arh Celok Lek. 2011 Nov-Dec;139(11-12):736-42
pubmed: 22338468
Open Access Maced J Med Sci. 2017 Nov 24;5(7):909-914
pubmed: 29362617
JAMA. 2009 Dec 2;302(21):2323-9
pubmed: 19952319
BMJ. 2021 Sep 21;374:n2132
pubmed: 34548312
Curr Opin Anaesthesiol. 2020 Apr;33(2):156-161
pubmed: 31904697
Crit Care Med. 2021 Nov 1;49(11):e1063-e1143
pubmed: 34605781
J Clin Med. 2020 May 19;9(5):
pubmed: 32438747
Saudi Med J. 2012 Apr;33(4):382-7
pubmed: 22485232
Nat Med. 2021 Aug;27(8):1317-1319
pubmed: 34312557
Chest. 1992 Jun;101(6):1644-55
pubmed: 1303622
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Ann Emerg Med. 2019 Oct;74(4):580-591
pubmed: 30982631
BMC Med Res Methodol. 2014 Feb 18;14:25
pubmed: 24548571
J Clin Epidemiol. 2021 Jun;134:178-189
pubmed: 33789819
BMC Med. 2015 May 01;13:104
pubmed: 25934044
Lancet. 2010 Feb 6;375(9713):463-74
pubmed: 20097417
PLoS One. 2015 Mar 11;10(3):e0118241
pubmed: 25760346
BMJ Open. 2013 Feb 14;3(2):
pubmed: 23418298
J Antimicrob Chemother. 2019 Nov 1;74(11):3352-3361
pubmed: 31325313
Am J Respir Crit Care Med. 2008 Mar 1;177(5):498-505
pubmed: 18096708
Ann Intensive Care. 2021 Oct 12;11(1):145
pubmed: 34636974
Gastroenterol Res Pract. 2017;2017:3457614
pubmed: 28607552
Am J Respir Crit Care Med. 2014 Nov 15;190(10):1102-10
pubmed: 25295709
Crit Care. 2014 Mar 10;18(2):R44
pubmed: 24612487
Front Neurol. 2017 Apr 24;8:153
pubmed: 28484421
PLoS Med. 2016 Nov 29;13(11):e1002184
pubmed: 27898664
JAMA. 2009 Sep 9;302(10):1059-66
pubmed: 19738090
Stat Med. 2003 Sep 15;22(17):2693-710
pubmed: 12939780
JAMA Intern Med. 2016 Sep 1;176(9):1266-76
pubmed: 27428731
Mitochondrion. 2014 May;16:50-4
pubmed: 24246912
Am J Epidemiol. 1986 Nov;124(5):719-23
pubmed: 3766505
Infect Dis (Lond). 2022 Jun;54(6):387-402
pubmed: 35175169
J Immunol Res. 2016;2016:3530752
pubmed: 27597981
Arch Intern Med. 2008 Oct 13;168(18):2000-7; discussion 2007-8
pubmed: 18852401
Am J Respir Crit Care Med. 2021 Jan 15;203(2):202-210
pubmed: 32757963
N Engl J Med. 2018 Jul 19;379(3):236-249
pubmed: 29781385
Chest. 2007 Jan;131(1):9-19
pubmed: 17218551
Crit Care. 2009;13(3):R83
pubmed: 19493352
Crit Care Clin. 2011 Apr;27(2):253-63
pubmed: 21440200
Cochrane Database Syst Rev. 2017 Oct 12;10:CD007498
pubmed: 29025194
Anaesthesiol Intensive Ther. 2021;53(3):207-214
pubmed: 34006044
J Korean Med Sci. 2019 Apr 15;34(14):e110
pubmed: 30977312
Acta Med Iran. 2015;53(9):562-7
pubmed: 26553084